Completes $77 million debt-for-equity exchange with Series C noteholders and senior secured lenders at premiums of 60% and 30% to the 5 day VWAP Achieves aggregate reduction in debt of $118 million since June 30, 2020, resulting in current indebtedness of $105 million Gains access to $4.6 million

BUENA, N.J. , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq

BUENA, N.J. , Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020 . Financial Highlights Third Quarter 2020 vs.

Scheduled to Reconvene on December 16 , 2020 Company Urgently Encourages Stockholders to Vote BUENA, N.J. , Nov. 25, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of

Scheduled to Reconvene on November 25 , 2020 Company Urgently Encourages Stockholders to Vote BUENA, N.J. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of

Scheduled to Reconvene on November 11 , 2020 Company Urgently Encourages Stockholders to Vote BUENA, N.J. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of

BUENA, N.J. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible

BUENA, N.J. , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2020 . Financial Highlights Second Quarter 2020 vs.

BUENA, N.J. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19 th , 2020 to discuss the 2 nd quarter 2020 financial results and business

BUENA, N.J. , July 20, 2020 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, announced the closing of the issuance of $13.8 million aggregate principal amount of 9.5% Series C Senior Convertible Notes due